TAK
Price
$14.99
Change
+$0.19 (+1.28%)
Updated
Aug 15, 03:50 PM (EDT)
Capitalization
46.65B
76 days until earnings call
ZTS
Price
$154.82
Change
+$1.76 (+1.15%)
Updated
Aug 15, 02:06 PM (EDT)
Capitalization
67.83B
76 days until earnings call
Interact to see
Advertisement

TAK vs ZTS

Header iconTAK vs ZTS Comparison
Open Charts TAK vs ZTSBanner chart's image
Takeda Pharmaceutical
Price$14.99
Change+$0.19 (+1.28%)
Volume$200
Capitalization46.65B
ZOETIS
Price$154.82
Change+$1.76 (+1.15%)
Volume$4.67K
Capitalization67.83B
TAK vs ZTS Comparison Chart in %
Loading...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TAK vs. ZTS commentary
Aug 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TAK is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2025
Stock price -- (TAK: $14.80 vs. ZTS: $153.06)
Brand notoriety: TAK: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TAK: 56% vs. ZTS: 78%
Market capitalization -- TAK: $46.65B vs. ZTS: $67.83B
TAK [@Pharmaceuticals: Generic] is valued at $46.65B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $67.83B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TAK’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • TAK’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, both TAK and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TAK’s TA Score shows that 6 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).

  • TAK’s TA Score: 6 bullish, 4 bearish.
  • ZTS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than TAK.

Price Growth

TAK (@Pharmaceuticals: Generic) experienced а +3.06% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +3.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.39%. For the same industry, the average monthly price growth was +69.29%, and the average quarterly price growth was +80.56%.

Reported Earning Dates

TAK is expected to report earnings on Oct 30, 2025.

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.39% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($67.8B) has a higher market cap than TAK($46.7B). TAK has higher P/E ratio than ZTS: TAK (51.15) vs ZTS (26.34). TAK YTD gains are higher at: 11.782 vs. ZTS (-5.140). TAK has higher annual earnings (EBITDA): 1.13T vs. ZTS (3.91B). ZTS has less debt than TAK: ZTS (6.75B) vs TAK (4.51T). TAK has higher revenues than ZTS: TAK (4.48T) vs ZTS (9.29B).
TAKZTSTAK / ZTS
Capitalization46.7B67.8B69%
EBITDA1.13T3.91B28,794%
Gain YTD11.782-5.140-229%
P/E Ratio51.1526.34194%
Revenue4.48T9.29B48,245%
Total Cash419BN/A-
Total Debt4.51T6.75B66,756%
FUNDAMENTALS RATINGS
TAK vs ZTS: Fundamental Ratings
TAK
ZTS
OUTLOOK RATING
1..100
209
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
8819
PRICE GROWTH RATING
1..100
5461
P/E GROWTH RATING
1..100
3584
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as ZTS (35) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (88) in the Pharmaceuticals Generic industry is in the same range as TAK (100) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to TAK’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for TAK (88) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew significantly faster than TAK’s over the last 12 months.

TAK's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to ZTS’s over the last 12 months.

TAK's P/E Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (84) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TAKZTS
RSI
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
39%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
40%
Bullish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 22 days ago
45%
Bearish Trend 16 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
32%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FELG39.240.07
+0.18%
Fidelity Enhanced Large Cap Growth ETF
ONOF35.760.05
+0.15%
Global X Adaptive US Risk Management ETF
IWMW39.530.01
+0.03%
iShares Russell 2000 BuyWrite ETF
LFDR175.19N/A
N/A
LifeX Durable Income ETF
OSEA29.20-0.14
-0.48%
Harbor International Compounders ETF

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+0.41%
ELAN - ZTS
46%
Loosely correlated
+1.07%
VTRS - ZTS
44%
Loosely correlated
+2.69%
PAHC - ZTS
41%
Loosely correlated
-1.26%
HLN - ZTS
38%
Loosely correlated
+0.10%
AMRX - ZTS
38%
Loosely correlated
-0.11%
More